Sensitivity and coverage for disease monitoring with cfDNA
Disease progression and resistance monitoring studies require low cost detection without sacrificing sensitivity. The MassARRAY® System can detect variants as low as 0.1% allele frequency at a low cost, making it ideally suited for disease monitoring.
While liquid biopsies provide easier access to tumor cells and DNA, they don’t necessarily provide enough. With just a few copies of circulating tumor DNA (ctDNA) per mL of plasma, you cannot afford to run multiple tests to detect all emerging resistance markers. The multiplexing capability of the UltraSEEK® chemistry makes it easy to detect over 100 variants, including insertions and deletions, using cfDNA from a single blood draw.
